Immunic, Inc. (NASDAQ:IMUX) Given Consensus Recommendation of “Buy” by Brokerages

Immunic, Inc. (NASDAQ:IMUX) has received a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $11.20.

Several brokerages have weighed in on IMUX. Piper Sandler reiterated an “overweight” rating and issued a $28.00 target price on shares of Immunic in a report on Tuesday, July 16th. B. Riley started coverage on shares of Immunic in a report on Tuesday, August 27th. They set a “buy” rating and a $6.00 target price on the stock. StockNews.com upgraded shares of Immunic from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th. Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a research note on Monday, September 9th. Finally, Leerink Partners reissued an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a research note on Monday, September 9th.

Hedge Funds Weigh In On Immunic

Several institutional investors and hedge funds have recently bought and sold shares of the company. BVF Inc. IL purchased a new stake in shares of Immunic during the 1st quarter valued at $11,752,000. Janus Henderson Group PLC acquired a new position in Immunic during the first quarter valued at $9,266,000. Vanguard Group Inc. boosted its stake in shares of Immunic by 100.7% in the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after buying an additional 1,703,047 shares during the last quarter. Gratus Capital LLC boosted its position in Immunic by 15.1% in the 4th quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock worth $2,912,000 after purchasing an additional 254,999 shares in the last quarter. Finally, Ikarian Capital LLC grew its position in Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after buying an additional 1,162,378 shares during the period. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Price Performance

IMUX stock opened at $1.52 on Monday. Immunic has a 12 month low of $0.95 and a 12 month high of $1.92. The firm’s 50-day moving average is $1.40 and its 200 day moving average is $1.31. The company has a market capitalization of $136.92 million, a PE ratio of -0.83 and a beta of 1.82.

Immunic (NASDAQ:IMUX) last issued its earnings results on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. During the same quarter in the previous year, the business earned ($0.54) EPS. Sell-side analysts forecast that Immunic will post -0.92 EPS for the current fiscal year.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.